Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Benzinga's Top Downgrades

Benzinga's Top Downgrades

Analysts at RBC Capital downgraded Dominion Diamond Corp (NYSE: DDC) from Outperform to Sector Perform. Dominion Diamond shares fell 3.32 percent to close at $10.78 on Friday.

Morgan Stanley downgraded Occidental Petroleum Corporation (NYSE: OXY) from Overweight to Equal-weight. Occidental Petroleum shares fell 0.20 percent to close at $75.45 on Friday.

Cowen & Company downgraded LyondellBasell Industries NV (NYSE: LYB) from Outperform to Market Perform. LyondellBasell shares fell 0.58 percent to $80.00 in pre-market trading.

Analysts at Jefferies downgraded SAP SE (ADR) (NYSE: SAP) from Hold to Underperform. SAP shares declined 1.80 percent to $77.03 in pre-market trading.

Macquarie downgraded Vodafone Group Plc (ADR) (NASDAQ: VOD) from Outperform to Neutral. Vodafone shares declined 2.12 percent to $30.51 in pre-market trading.

DA Davidson downgraded U.S. Silica Holdings Inc (NYSE: SLCA) from Buy to Neutral. US Silica shares fell 3.03 percent to $32.60 in pre-market trading.

Analysts at JP Morgan downgraded Axiall Corp (NYSE: AXLL) from Overweight to Neutral. The target price for Axiall has been raised from $26.50 to $33. Axiall shares jumped 26.15 percent to close at $32.56 on Friday.

Latest Ratings for DDC

Jul 2017MaintainsNeutral
Jul 2017DowngradesBuyNeutral
Jul 2017DowngradesBuyHold

View More Analyst Ratings for DDC
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (DDC + AXLL)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Goldman Sachs: 3 Questions For Agios Pharmaceuticals

BioSpecifics Technologies Reveals Positive Top-Line Results from Stage 2 Study Of CCH For Treatment of Human Lipoma